GDC-4198 clinical trials

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

This study is looking at new treatments for advanced breast cancer. It tests a new drug called GDC-4198, alone or with giredestrant, and compares it to another combination (abemaciclib + giredestrant). The aim is to find safer and more effective ways to treat this type of cancer.